New daily pill could tame bone sarcomas
NCT ID NCT07193550
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a daily oral drug called zanzalintinib in 70 adults with advanced or metastatic bone sarcomas that cannot be removed by surgery. The study includes four groups based on sarcoma type. Researchers will check if the drug is safe and helps control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanzalintinib (a daily oral drug)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced bone sarcomas that have spread.
- What could go wrong
- This is an early phase 2 trial with only 70 people, so results may not apply to everyone. The drug may cause side effects or not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a targeted pill stall advanced sarcomas?
- A simple blood test may reveal how ewing sarcoma responds to therapy
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Targeted radiation zaps childhood brain tumors in early trial